DE60100750D1 - NEUE KRISTALLINE FORM VON N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMINSÄURE UND VERFAHREN FÜR IHRE HERSTELLUNG - Google Patents

NEUE KRISTALLINE FORM VON N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMINSÄURE UND VERFAHREN FÜR IHRE HERSTELLUNG

Info

Publication number
DE60100750D1
DE60100750D1 DE60100750T DE60100750T DE60100750D1 DE 60100750 D1 DE60100750 D1 DE 60100750D1 DE 60100750 T DE60100750 T DE 60100750T DE 60100750 T DE60100750 T DE 60100750T DE 60100750 D1 DE60100750 D1 DE 60100750D1
Authority
DE
Germany
Prior art keywords
pyrrolo
pyrimidin
dihydro
benzoyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60100750T
Other languages
English (en)
Other versions
DE60100750T2 (de
Inventor
Christopher Chelius
Marie Reutzel-Edens
Van Den Berghe Snorek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60100750(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60100750D1 publication Critical patent/DE60100750D1/de
Publication of DE60100750T2 publication Critical patent/DE60100750T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
DE60100750T 2000-02-25 2001-02-12 NEUE KRISTALLINE FORM VON N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMINSÄURE UND VERFAHREN FÜR IHRE HERSTELLUNG Expired - Lifetime DE60100750T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25
US184964P 2000-02-25
PCT/US2001/001229 WO2001062760A2 (en) 2000-02-25 2001-02-12 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Publications (2)

Publication Number Publication Date
DE60100750D1 true DE60100750D1 (de) 2003-10-16
DE60100750T2 DE60100750T2 (de) 2004-07-29

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60100750T Expired - Lifetime DE60100750T2 (de) 2000-02-25 2001-02-12 NEUE KRISTALLINE FORM VON N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMINSÄURE UND VERFAHREN FÜR IHRE HERSTELLUNG

Country Status (36)

Country Link
US (1) US7138521B2 (de)
EP (1) EP1259513B1 (de)
JP (1) JP4846158B2 (de)
KR (1) KR100744917B1 (de)
CN (1) CN1183135C (de)
AR (1) AR029471A1 (de)
AT (1) ATE249462T1 (de)
AU (1) AU777047B2 (de)
BR (1) BR0108604A (de)
CA (1) CA2400155C (de)
CO (1) CO5261585A1 (de)
CZ (1) CZ303772B6 (de)
DE (1) DE60100750T2 (de)
DK (1) DK1259513T3 (de)
DZ (1) DZ3283A1 (de)
EA (1) EA004684B1 (de)
EG (1) EG24073A (de)
ES (1) ES2206403T3 (de)
HK (1) HK1051856A1 (de)
HR (1) HRP20020701B1 (de)
HU (1) HU229704B1 (de)
IL (2) IL150480A0 (de)
MX (1) MXPA02008242A (de)
MY (1) MY124784A (de)
NO (1) NO323422B1 (de)
NZ (1) NZ519796A (de)
PE (1) PE20011082A1 (de)
PL (1) PL208061B1 (de)
PT (1) PT1259513E (de)
SI (1) SI1259513T1 (de)
SK (1) SK287375B6 (de)
SV (1) SV2002000321A (de)
TW (1) TWI237024B (de)
UA (1) UA72791C2 (de)
WO (1) WO2001062760A2 (de)
ZA (1) ZA200205265B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
EP1947936A4 (de) * 2005-11-04 2010-02-10 Merck & Co Inc Verfahren zur verwendung von saha und bortezomib für die behandlung von krebs
EP1942907A2 (de) * 2005-11-04 2008-07-16 Merck and Co., Inc. Verfahren zur verwendung von saha und erlotinib zur krebsbehandlung
ES2354843T3 (es) * 2006-08-14 2011-03-18 Sicor, Inc. Formas cristalinas de diácido de pemetrexed y procedimientos para la preparación de las mismas.
EP1957497B1 (de) 2006-08-14 2015-09-30 Sicor, Inc. Verfahren zur herstellung von zwischenprodukten aus pemetrexed
ATE492547T1 (de) 2006-08-14 2011-01-15 Sicor Inc Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed- disäure
EP1934226A2 (de) * 2006-08-14 2008-06-25 Sicor, Inc. Pemetrexed-diacid von hoher reinheit und verfahren zu dessen herstellung
AU2007317921A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using SAHA and Bortezomib for treating multiple myeloma
KR20100014854A (ko) * 2007-04-03 2010-02-11 닥터 레디스 레보러터리즈 리미티드 페메트렉세드의 고체 형태
CN101417998B (zh) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
US20090181990A1 (en) 2007-12-23 2009-07-16 Patel Nileshkumar S Stable amorphous form of pemetrexed disodium
EP2334685A4 (de) * 2008-09-08 2011-10-26 Reddys Lab Ltd Dr Amorphes pemetrexed-dinatrium
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
EP2504341A1 (de) 2009-11-24 2012-10-03 Azad Pharmaceutical Ingredients AG Neue kristalline form von pemetrexed-dinatrium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
AU2011363636B2 (en) * 2011-03-25 2016-03-17 Scinopharm Taiwan Ltd Process for the production of a pemetrexed salt
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (en) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Crystalline pemetrexed dipotassium process
EP2953616A2 (de) 2013-02-06 2015-12-16 Cipla House Pemetrexedkomplexe und pharmazeutische zusammensetzungen mit pemetrexedkomplexen
WO2014167585A1 (en) 2013-04-12 2014-10-16 Actavis Group Ptc Ehf. Pemetrexed formulation
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
EP3008064B1 (de) 2013-06-14 2017-11-22 Synthon B.V. Stabile argininsalze von pemetrexed und zusammensetzungen davon
WO2015008221A1 (en) 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Novel crystalline forms of pemetrexed tromethamine salts
CN110051625A (zh) 2013-10-03 2019-07-26 富士胶片株式会社 注射液制剂及其制造方法
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
CA3015436C (en) * 2014-10-30 2020-07-21 Scinopharm Taiwan, Ltd. Crystalline forms of pemetrexed diacid and manufacturing processes therefor
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
WO2019073482A1 (en) * 2017-10-10 2019-04-18 Sun Pharmaceutical Industries Limited INTRAVENOUS INFUSION TYPE DOSAGE FORM FOR PETREXED

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
JP2000516961A (ja) * 1996-08-30 2000-12-19 イーライ・リリー・アンド・カンパニー 非古典的ピロロ［２，３―ｄ］ピリミジン抗葉酸物質
UA53742C2 (uk) * 1997-09-26 2003-02-17 Елі Ліллі Енд Компані Спосіб одержання альдегідів, які використовують при синтезі сполук, цінних як антифолати
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
WO2001014379A2 (en) * 1999-08-23 2001-03-01 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Also Published As

Publication number Publication date
SV2002000321A (es) 2002-07-16
HUP0204232A2 (hu) 2003-04-28
DK1259513T3 (da) 2004-01-12
CO5261585A1 (es) 2003-03-31
ES2206403T3 (es) 2004-05-16
US20030216416A1 (en) 2003-11-20
IL150480A (en) 2007-12-03
IL150480A0 (en) 2002-12-01
EP1259513A2 (de) 2002-11-27
EA004684B1 (ru) 2004-06-24
HRP20020701A2 (en) 2003-12-31
HRP20020701B1 (en) 2011-02-28
HK1051856A1 (en) 2003-08-22
MXPA02008242A (es) 2002-11-29
EG24073A (en) 2008-05-11
CN1406238A (zh) 2003-03-26
NZ519796A (en) 2003-01-31
DE60100750T2 (de) 2004-07-29
KR100744917B1 (ko) 2007-08-01
HU229704B1 (en) 2014-05-28
JP4846158B2 (ja) 2011-12-28
WO2001062760A2 (en) 2001-08-30
CA2400155A1 (en) 2001-08-30
CA2400155C (en) 2009-09-15
UA72791C2 (uk) 2005-04-15
PT1259513E (pt) 2004-02-27
NO323422B1 (no) 2007-04-30
JP2003530321A (ja) 2003-10-14
SK287375B6 (sk) 2010-08-09
US7138521B2 (en) 2006-11-21
AU777047B2 (en) 2004-09-30
DZ3283A1 (fr) 2001-08-30
BR0108604A (pt) 2002-11-19
TWI237024B (en) 2005-08-01
SK11862002A3 (sk) 2003-01-09
ATE249462T1 (de) 2003-09-15
AU3445101A (en) 2001-09-03
AR029471A1 (es) 2003-07-02
PL356423A1 (en) 2004-06-28
NO20023974L (no) 2002-08-21
CN1183135C (zh) 2005-01-05
PL208061B1 (pl) 2011-03-31
HUP0204232A3 (en) 2006-01-30
WO2001062760A3 (en) 2001-12-06
ZA200205265B (en) 2003-11-11
CZ20022875A3 (cs) 2003-02-12
EA200200905A1 (ru) 2003-02-27
KR20020075449A (ko) 2002-10-04
MY124784A (en) 2006-07-31
EP1259513B1 (de) 2003-09-10
NO20023974D0 (no) 2002-08-21
PE20011082A1 (es) 2001-10-22
CZ303772B6 (cs) 2013-05-02
SI1259513T1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
DE60100750D1 (de) NEUE KRISTALLINE FORM VON N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMINSÄURE UND VERFAHREN FÜR IHRE HERSTELLUNG
CA2379560A1 (en) Purine derivatives inhibitors of tyrosine protein kinase syk
DE60119283D1 (de) Verfahren zur herstellung von 3-hydroxypicolinsäure-derivaten
WO2001014379A3 (en) A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
EE200200665A (et) Triasolo (4,5-d)pürimidiiniühendi uus kristalne ja amorfne vorm, meetod selle valmistamiseks ning kasutamine
DE60040905D1 (de) VERFAHREN ZUR HERSTELLUNG VON (E)-(6-i2-i4-(4-FLUORPHENYL)-6-ISOPROPYL-2-iMETHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL VINYL (4R,6S)-2,2-DIMETHYLi1,3 DIOXAN-4-YL)ESSIGSÄURE-TERT-BUTYLESTER
DE60116272D1 (de) Malonsäure derivate, verfahren zu ihrer herstellung, ihre verwendung als inhibitor der faktor xa aktivität und pharmazeutische zusammensetzungen diese enthaltend
WO2003014080A3 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
DE50106993D1 (de) Neue 7-azaindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung
DE50305374D1 (de) Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
DE60122704D1 (de) Herstellung von iminodiessigsäure-derivaten aus monoethanolamin-substraten
HUP0402253A3 (en) Process for the purification of n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-phenyl]-n-ethylacetamide(zaleplon) and the preparation of its novel crystalline forms and pharmaceutical compositions containing the latters
BR1100847A (pt) Derivados de 2- [4 - (4-azolilbutil) -1- piperazinil] -pirimidina, compostos, processo de preparação dos compostos, utilização dos compostos, e, composições farmacêuticas
DE60230629D1 (de) Verwendung von 2,5-dihydroxybenzolsulfonsäure-derivaten bei der herstellung eines medikaments zur verstärkung der wirkung anderer arzneimittel zur behandlung der erektilen dysfunktion
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
EE200000619A (et) Oktahüdro-6,10-diokso-6H-püridasino[1,2-a][1,2]diasepiin-1-karboksüülhappe derivaadid, nende ratseemiline segu, valmistamismeetod ja kasutamine ning vaheühendid
ATE179424T1 (de) N-heteroaryl substituierte propanamid-derivate brauchbar zur behandlung cardiovascularer krankheiten
DE60125915D1 (de) Verfahren zur herstellung von quinolin-derivaten und ihre zwischenstufen
DE60204014D1 (de) Chlormethylierung von thiophene
EE200200410A (et) Meetod atsetüülamidiniofenüülalanüültsükloheksüülglütsüülpüridinioalaniinamiidide valmistamiseks ning selleks vajalikud lähte- ja vaheühendid
DE60208365D1 (de) Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln
DE60304703D1 (de) Neue 3-(4-oxo-4h-chromen-2-yl)-(1h)-quinolin-4-one-derivate; verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
DE50206070D1 (de) Verfahren zur Herstellung von copolymeren hydrophob modifizierten Polyglutaminsäurederivaten und ihre Verwendung
DE60031315D1 (de) Verfahren zur Herstellung von Derivaten von i(1,5-Diaryl)pyrazol-3-ylöpropansäure
DE60117846D1 (de) Herstellung von 6-aminocaprinsäurealkylestern

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN